Thus, we posit that STING agonists can acutely suppress cancer pain through direct effects, while providing long term relief from bone cancer-induced pain by suppressing osteoclast-mediated bone destruction and relieving local tumor burden (Fig. 10). This evidence concerns the gene STING1 and bone neoplasm.